As Novartis drops $500 million on DTx Pharma and $250 million on the Calypso buyout and Takeda places a $580 million bet on AcuraStem’s ALS treatments, CNS pharmaceuticals, and biotech are funneling into oligonucleotide research and clinical development.
This July, an exclusive group of 100+ senior decision-makers united at the 4th Oligonucleotides for CNS Summit to tackle the hottest challenges from a lens of biopharma challenges and innovations. Are you ready to elevate your unique value proposition in overcoming their pipeline bottlenecks?
2024 Partners Included:
CNS Biopharma Need Your Help With:
Oligonucleotide Manufacturing & Analysis
Advanced In Vitro Models
State-of-the-Art In Vivo Models
Clinical CRO Expertise
Innovative Drug Delivery Solutions
Cutting-edge Discovery & AI
Why Partner?
Educate the industry:
speak on the main agenda to leverage your expertise alongside senior KOLs from biopharma to gain credibility and build trust, distinguishing your unique value proposition from your competitors
Gain brand visibility:
broaden your company’s exposure to our intimate audience of 150+ senior biopharma leaders
Meet senior CNS decision makers from large pharma increasing their spend in neuroscience R&D,
plus well-established and new biotechs expanding their CNS pipelines prioritizing targeted therapies the help of your dedicated partnership director and on-site team, and build connections with your target audience you’ve been looking to meet
Secure new business
with exclusive market insights selectively curated by the Hanson Wade team to get into the crux of your customers’ pain points and differentiate your brand as what your customers are looking for
Cement
your company as the leading provider for your service in neurodegenerative research and development
